News

Scientists argue that scientific and political changes will make adaptive pathways the preferred approach to make new treatments available

New Cardiac Safety Methodology from iCardiac Technologies Offers Earlier Cardiac Safety Characterization and Significant Cost Savings

For robust scientific assessment more information on safety and efficacy needed.

While the issue of adverse drug reaction (ADR) reporting is apparent in hospital systems, a deeper and uninvestigated problem resides within the process of ADRs: the patient.

There is not enough available evidence yet for any of the experimental therapies for the Ebola virus disease to draw conclusions on their safety or efficacy when used in Ebola patients, according to an interim report published by the European Medicines Agency.

Medidata took a look at how eCRF design complexity correlates with the number of migrations performed while a study is actively collecting subject data.

In the coming year, we expect to see sponsors focused on making better use of their data investments that are now electronically available through EDC and other systems.

Granted Permission to Host its Own Web Version of the EQ-5D

PPD and ERT announced a strategic partnership.

Quanterix announced “Simoa Accelerator” – a dedicated laboratory environment for clinical sample testing and development allowing broader access to an advanced diagnostic technology that has been fueling research in oncology, neurology, cardiology, infectious disease, etc.

Quanterix announced the opening of The Simoa Accelerator.

CRF Health announced an agreement with EuroQol to launch the EQ-5D web system on its TrialMax Web software platform.

Agreement expands innovative data collection offerings for biopharmaceutical clients

WIRB-Copernicus Group announced that it has been chosen by Cancer Treatment Centers of America to expand its clinical research program.

Strategy will enable CTCA to expand its clinical research capabilities while maintaining the highest standard of human subject protection

It’s clear that the value clinical trials bring to the health and well being of our existence is being recognized and expectations from the public are high.

The development and approval of new vaccines and antivirals to contain and treat the Ebola virus outbreak has become a top priority for the federal government and Congress.

EFPIA is pleased to announce today the official appointment of Joe Jimenez, CEO of Novartis, as its new President.

EFPIA has announced the official appointment of Joe Jimenez, CEO of Novartis, as its new President.

The European Forum for GCP (EFGCP) Geriatric Medicines Working Party is organizing a multi-stakeholder workshop, “Excluded Older People from Clinical Research”

SCRS announced a two-year collaboration with Clinical Ink.

Acquisition Enriches Medidata’s Comprehensive Risk-Based Monitoring Solution, Enabling Safer, Faster and More Insightful Clinical Trial Reviews

SCRS announced a two-year collaboration with Clinical Ink

Medidata announced the availability is enriched solution for risk-based monitoring.

PCORI is launching a $50 million program to fund research on the comparative effectiveness of various approaches for diagnosing and treating hepatitis C.

TrialScope announced the latest release of its PharmaCM platform (v.2.2)

TrialScope announced general availability of the latest release of the PharmaCM platform

Comprehend CEO Rick Morrison shares his thoughts on 2015 predictions for clinical R&D.

The conclusions on vaccination that European Union health ministers adopted on December 1 contain several sound thoughts.